|Day Low/High||165.58 / 166.81|
|52 Wk Low/High||94.82 / 165.95|
Start 2017 on the right foot by selling your holdings in these five stocks.
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
Here's a window into what institutional investors may be doing and how to profit from that.
Too many turn bearish too quickly just because they can't find any entry points.
Shares of Biogen and Alexion Pharmaceuticals took a hit Tuesday after their promising new products failed clinical trials.
U.S. indices are up as oil continues its climb past $50 a barrel.
Crude prices were also falling following the BOJ's decision to keep its monetary policy unchanged.
The next potential support levels are the $120 and $100 areas from 2013.
ILMN's three-month at-the-money implied volatility is at about the median level.
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Stocks pared losses, though remained in the red by close as markets weighed comments from Federal Reserve Chair Janet Yellen that equity valuations were possibly stretched.
Herbalife (HLF) rallied after boosting full-year earnings forecasts as sales in China showed strength.
Here are healthcare stocks of all shares and sizes with strong charts.
Do you need to pick one name? Biotech has carried with it a lasting resiliency like few other sectors. Perhaps it is driven by optimism and hope. Perhaps it is driven by the fear of suffering or watching someone suffer from the very illnesses these ...
As these examples illustrate, it's just good risk management.
Some growth leaders in the sector are getting technical support.